Tags: 
Moderna published (https://medcitynews.com/2020/09/moderna-publishes-phase-iii-covid-19-vaccine-study-protocol-as-trial-enrolls-more-than-80-of-participants/?rf=1) that the Phase III Covid-19 vaccine study protocol enrolled 25,296 of its planned 30,000 participants which is more than 80% of participants. Of all enrolled subjects, 10,025 have received the full vaccine. This mRNA-1273 Moderna’s vaccine consists of two shots – one delivered on day 1, and a booster shot that participants receive on day 29.
Moderna is this Phase III study (https://www.modernatx.com/sites/default/files/mRNA-1273-P301-Protocol.pdf) under partnership with the National Institutes of Health and the Department of Health and Human Services’ Biomedical Advanced Research and Development Authority, under HHS’ Operation Warp Speed.
The mRNA-1273 vaccine uses messenger RNA technology, similar to the BNT162 vaccines developed by Pfizer and Germany’s BioNTech.
Other Covid-19 vaccines in late-stage development is the one from AstraZeneca, which is developing its vaccine, AZD1222, with the University of Oxford.
Specializing in rare disease, Boston Biotech Clinical Research works with biotech, pharmaceutical, device companies and investors to streamline the clinical trial process. Our experienced team helps each client reach their specific goals by customizing a clinical and regulatory road map of simplified programs and streamlined protocols to meet our clients’ requirements.